HC Wainwright Research Analysts Raise Earnings Estimates for Precigen, Inc. (NASDAQ:PGEN)

Precigen, Inc. (NASDAQ:PGEN) – Stock analysts at HC Wainwright upped their Q3 2024 EPS estimates for Precigen in a research report issued to clients and investors on Thursday, August 15th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will earn ($0.07) per share for the quarter, up from their previous forecast of ($0.09). HC Wainwright has a “Buy” rating and a $4.00 price target on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Precigen’s Q4 2024 earnings at ($0.05) EPS, FY2024 earnings at ($0.43) EPS, Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.20) EPS and FY2028 earnings at $0.43 EPS.

A number of other research firms also recently commented on PGEN. Stifel Nicolaus boosted their target price on Precigen from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Monday, June 3rd. StockNews.com upgraded shares of Precigen to a “sell” rating in a research report on Thursday, August 1st. Cantor Fitzgerald reissued an “overweight” rating on shares of Precigen in a research note on Wednesday, May 15th. Finally, JMP Securities cut their target price on shares of Precigen from $14.00 to $7.00 and set a “market outperform” rating for the company in a research report on Thursday, August 15th. Two analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Precigen has a consensus rating of “Hold” and a consensus price target of $7.00.

Precigen Stock Down 1.7 %

NASDAQ:PGEN opened at $1.13 on Monday. Precigen has a fifty-two week low of $0.84 and a fifty-two week high of $1.93. The firm’s fifty day simple moving average is $1.48 and its 200-day simple moving average is $1.46. The stock has a market cap of $285.62 million, a PE ratio of -2.90 and a beta of 1.73.

Insider Buying and Selling at Precigen

In other news, SVP Jeffrey Thomas Perez acquired 58,823 shares of the company’s stock in a transaction dated Friday, August 9th. The shares were bought at an average price of $0.85 per share, for a total transaction of $49,999.55. Following the completion of the purchase, the senior vice president now directly owns 743,097 shares of the company’s stock, valued at approximately $631,632.45. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 44.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of PGEN. Patient Capital Management LLC raised its position in shares of Precigen by 16.2% in the 4th quarter. Patient Capital Management LLC now owns 15,983,700 shares of the biotechnology company’s stock valued at $21,418,000 after purchasing an additional 2,230,524 shares in the last quarter. Sanders Morris Harris LLC acquired a new stake in Precigen in the first quarter valued at $1,022,000. EntryPoint Capital LLC bought a new position in Precigen during the 1st quarter valued at $31,000. Opaleye Management Inc. grew its holdings in Precigen by 9.0% during the 4th quarter. Opaleye Management Inc. now owns 1,012,500 shares of the biotechnology company’s stock worth $1,357,000 after acquiring an additional 84,000 shares in the last quarter. Finally, Panagora Asset Management Inc. bought a new stake in shares of Precigen in the 4th quarter worth about $407,000. Hedge funds and other institutional investors own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.